Lung cancer: advances in treatment
S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.